Eli Lilly 2008 Annual Report Download - page 13
Download and view the complete annual report
Please find page 13 of the 2008 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3 -
4 -
5 -
6 -
7 -
8 -
9 -
10 -
11 -
12 -
13 -
14 -
15 -
16 -
17 -
18 -
19 -
20 -
21 -
22 -
23 -
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
 |
 |
PORTFOLIO AND PIPELINE
11
IMC-11F8 for solid tumors
IMC-3G3 for solid tumors
IMC-18F1 for solid tumors
LY2599506 for type 2 diabetes
LY2624803 for insomnia
mGlu2/3 Prodrug for schizophrenia
NK-1 Antagonist for alcohol dependence
NERI IV for depression and ADHD
OpRA II for alcohol dependence
Solanezumab for Alzheimer’s disease
Survivin ASO for solid tumors
Tasisulam for solid tumors
TGF beta Antibody for chronic renal disease and solid tumors
TGF beta Inhibitor for solid tumors
Information is current as of February 17, 2009. The search for new drugs is risky and uncertain, and there are no guarantees. Remaining scientifi c and
regulatory hurdles may cause pipeline compounds to be delayed or even to fail to reach the market.